Epacadostat
- Generic Name
- Epacadostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Incyte Biosciences International Sàrl
- Target Recruit Count
- 10
- Registration Number
- NCT03277352
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- Conditions
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 129
- Registration Number
- NCT03260894
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇨🇦Sunnybrook Health Sciences, Odette Cancer Centre, Toronto, Ontario, Canada
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT03238638
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
- Conditions
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Chao Huang
- Target Recruit Count
- 15
- Registration Number
- NCT03217669
- Locations
- 🇺🇸
Clinical Research Center, Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 3
- Registration Number
- NCT03196232
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT03085914
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-10-08
- Target Recruit Count
- 41
- Registration Number
- NCT03006302
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT02959437
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Aduro Biotech, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02575807
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT02559492
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.